Detalhe da pesquisa
1.
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
Cell
; 184(2): 384-403.e21, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33450205
2.
The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Nature
; 525(7569): 384-8, 2015 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26331541
3.
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nat Med
; 24(4): 505-511, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29578538